181 related articles for article (PubMed ID: 3672079)
1. [Successful treatment of anemia in hemolysis patients using recombinant human erythropoietin. Maintenance dosage and serum concentration].
Stutz B; Rhyner K; Vögtli J; Binswanger U
Schweiz Med Wochenschr; 1987 Sep; 117(38):1397-402. PubMed ID: 3672079
[TBL] [Abstract][Full Text] [Related]
2. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
3. Human recombinant erythropoietin treatment in transfusion dependent anemic patients on maintenance hemodialysis.
Zehnder C; Blumberg A
Clin Nephrol; 1989 Feb; 31(2):55-9. PubMed ID: 2920469
[TBL] [Abstract][Full Text] [Related]
4. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
[TBL] [Abstract][Full Text] [Related]
5. [Human recombinant erythropoietin in the treatment of anemia in patients on long-term hemodialysis].
Boratyńska M; Szewczyk Z; Szepietowski T; Czyz W; Cybulski K; Bogucki J; Szczepański J
Przegl Lek; 1990; 47(11):741-5. PubMed ID: 2098840
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
7. Effect of recombinant human erythropoietin therapy on ambulatory blood pressure in normotensive and in untreated borderline hypertensive hemodialysis patients.
Lebel M; Kingma I; Grose JH; Langlois S
Am J Hypertens; 1995 Jun; 8(6):545-51. PubMed ID: 7662237
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
9. [The correction of anemia with a high requirement for transfusion in patients on maintenance hemodialysis by conventional and reduced doses of recombinant human erythropoietin].
Sivak L; Scuteri RM; Cavalli NH; Gotlieb D; López Blanco OA
Medicina (B Aires); 1992; 52(6):516-22. PubMed ID: 1340900
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of anemia in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
Prata MM; de Sousa FT; Barbas JV; da Costa AM; Vinhas J; Moreira P; Abrantes C; Lopes MC
Acta Med Port; 1990; 3(3):149-53. PubMed ID: 2220424
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
12. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
14. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of anemia in hemodialysis patients using recombinant human erythropoietin: advantages and disadvantages].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1989 Mar; 119(9):269-75. PubMed ID: 2711161
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
[TBL] [Abstract][Full Text] [Related]
17. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. Multicenter Study Group, Israel.
Yagil Y
Isr J Med Sci; 1997 Jan; 33(1):36-44. PubMed ID: 9203516
[TBL] [Abstract][Full Text] [Related]
18. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
[TBL] [Abstract][Full Text] [Related]
19. [Effectiveness of recombinant human erythropoietin in the treatment of transfusion-dependent anemia in patients on chronic dialysis].
Graf H; Mayer G; Cada EM; Thum J; Stummvoll HK
Wien Klin Wochenschr; 1987 Dec; 99(24):855-9. PubMed ID: 3439185
[TBL] [Abstract][Full Text] [Related]
20. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
